Format

Send to

Choose Destination
Mol Genet Genomic Med. 2016 May 10;4(5):504-12. doi: 10.1002/mgg3.223. eCollection 2016 Sep.

Concordance between whole-exome sequencing and clinical Sanger sequencing: implications for patient care.

Author information

1
Children's Hospital of Eastern Ontario Research Institute University of Ottawa Ottawa Ontario Canada.
2
Department of Human Genetics McGill UniversityMontréalQuébecCanada; McGill University and Genome Québec Innovation CenterMontréalQuébecCanada.
3
Children's Hospital of Eastern Ontario Research InstituteUniversity of OttawaOttawaOntarioCanada; Department of GeneticsChildren's Hospital of Eastern Ontario ResearchOttawaOntarioCanada.
4
Children's Hospital of Eastern Ontario Research InstituteUniversity of OttawaOttawaOntarioCanada; Division of Metabolics and Newborn ScreeningDepartment of PediatricsChildren's Hospital of Eastern OntarioOttawaOntarioCanada.

Abstract

The clinical translation of next-generation sequencing has created a paradigm shift in the diagnostic assessment of individuals with suspected rare genetic diseases. Whole-exome sequencing (WES) simultaneously examines the majority of the coding portion of the genome and is rapidly becoming accepted as an efficient alternative to clinical Sanger sequencing for diagnosing genetically heterogeneous disorders. Among reports of the clinical and diagnostic utility of WES, few studies to date have directly compared its concordance to Sanger sequencing, which is considered the clinical "gold standard". We performed a direct comparison of 391 coding and noncoding polymorphisms and variants of unknown significance identified by clinical Sanger sequencing to the WES results of 26 patients. Of the 150 well-covered coding variants identified by Sanger sequencing, 146 (97.3%) were also reported by WES. Nine genes were excluded from the comparison due to consistently low coverage in WES, which might be attributed to the use of older exome capture kits. We performed confirmatory Sanger sequencing of discordant variants; including five variants with discordant bases and four with discordant zygosity. Confirmatory Sanger sequencing supported the original Sanger report for three of the five discordant bases, one was shown to be a false positive supporting the WES data, and one result differed from both the Sanger and WES data. Two of the discordant zygosity results supported Sanger and the other two supported WES data. We report high concordance for well-covered coding variants, supporting the use of WES as a screening tool for heterogeneous disorders, and recommend the use of supplementary Sanger sequencing for poorly-covered genes when the clinical suspicion is high. Importantly, despite remaining difficulties with achieving complete coverage of the whole exome, 10 (38.5%) of the 26 compared patients were diagnosed through WES.

KEYWORDS:

Coverage; Sanger sequencing; rare diseases; whole‐exome sequencing

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center